Oxcia’s CEO Ulrika Warpman Berglund has been specially invited to give a presentation at the approaching DDR Summit in Boston January 30th – February 1st. The title is “What is Next for DDR Inhibitors Outside Oncology”. Oxcia is one of the pioneers in the DDR inhibitor and oxidative DNA damage domain.
DDR is short for DNA Damage Response – and refers to the processes the body uses to repair the damage that occurs to DNA. Many of the key players in the field will be at the DDR Summit including big pharma like AstraZeneca, Pfizer and Novartis as well as smaller biotechs like Repare therapeutics. The conference will cover the latest developments across discovery to clinical updates and novel insights from pioneering companies.
If you will attend the conference, do not miss the opportunity to meet up with Ulrika.